OS THERAPIES INC (OSTX) Stock Overview
USA - NYSEARCA:OSTX - US68764Y2072 - Common Stock
OSTX Key Statistics, Chart & Performance
The current stock price of OSTX is 2.25 USD. In the past month the price increased by 4.65%. In the past year, price decreased by -34.59%.
OSTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.62 | 385.71B | ||
| AMGN | AMGEN INC | 12.67 | 148.80B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 142.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.29 | 101.15B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 61.07B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.27 | 59.35B | ||
| ARGX | ARGENX SE - ADR | 81.59 | 46.29B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.67 | 38.56B | ||
| INSM | INSMED INC | N/A | 30.85B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.26B | ||
| NTRA | NATERA INC | N/A | 23.13B | ||
| BIIB | BIOGEN INC | 9.05 | 21.24B |
Related stock screener links
About OSTX
Company Profile
OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Rockville, Maryland and currently employs 4 full-time employees. The company went IPO on 2024-08-01. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. Its lead asset, OST-HER2, is an off-the-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides. OST-tADC is a tunable ADC with a plug-and-play platform that features tunable pH-sensitive silicone linkers (SiLinkers). Its clinical-stage cancer immunotherapy programs also include OST-AXAL for human papilloma virus (HPV)-associated cancers; OST-503 for non-small cell lung cancer (NSCLC) & glioblastoma; and OST-PSA for prostate cancer.
Company Info
OS THERAPIES INC
15825 Shady Grove Road, Suite 135
Rockville MARYLAND US
Employees: 4
Phone: 14102977793
OS THERAPIES INC / OSTX FAQ
What is the stock price of OS THERAPIES INC today?
The current stock price of OSTX is 2.25 USD. The price decreased by -2.6% in the last trading session.
What is the ticker symbol for OS THERAPIES INC stock?
The exchange symbol of OS THERAPIES INC is OSTX and it is listed on the NYSE Arca exchange.
On which exchange is OSTX stock listed?
OSTX stock is listed on the NYSE Arca exchange.
What is the price forecast or stock price prediction for OS THERAPIES INC stock?
10 analysts have analysed OSTX and the average price target is 13.26 USD. This implies a price increase of 489.33% is expected in the next year compared to the current price of 2.25. Check the OS THERAPIES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is OS THERAPIES INC worth?
OS THERAPIES INC (OSTX) has a market capitalization of 71.21M USD. This makes OSTX a Micro Cap stock.
How many employees does OS THERAPIES INC have?
OS THERAPIES INC (OSTX) currently has 4 employees.
What are the support and resistance levels for OS THERAPIES INC (OSTX) stock?
OS THERAPIES INC (OSTX) has a support level at 2.25 and a resistance level at 2.32. Check the full technical report for a detailed analysis of OSTX support and resistance levels.
Is OS THERAPIES INC (OSTX) expected to grow?
The Revenue of OS THERAPIES INC (OSTX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the OSTX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy OS THERAPIES INC (OSTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of OSTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of OSTX, evaluating the profitability, health, valuation and growth aspects
- OS THERAPIES INC (OSTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- OS THERAPIES INC (OSTX) Sales and EPS estimates to see what analysts future expectations are.
- OS THERAPIES INC (OSTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- OS THERAPIES INC (OSTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- OS THERAPIES INC (OSTX) Stock Chart to make your own analysis
- OS THERAPIES INC (OSTX) Latest news and press-releases to stay up to date.
Does OS THERAPIES INC (OSTX) stock pay dividends?
OSTX does not pay a dividend.
What is the Price/Earnings (PE) ratio of OS THERAPIES INC (OSTX)?
OS THERAPIES INC (OSTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.79).
What is the Short Interest ratio of OS THERAPIES INC (OSTX) stock?
The outstanding short interest for OS THERAPIES INC (OSTX) is 3.06% of its float. Check the ownership tab for more information on the OSTX short interest.
OSTX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to OSTX. When comparing the yearly performance of all stocks, OSTX is a bad performer in the overall market: 79.59% of all stocks are doing better.
OSTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OSTX. OSTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
OSTX Financial Highlights
Over the last trailing twelve months OSTX reported a non-GAAP Earnings per Share(EPS) of -0.79. The EPS decreased by -128.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -312.31% | ||
| ROE | -2162.75% | ||
| Debt/Equity | 0 |
OSTX Forecast & Estimates
10 analysts have analysed OSTX and the average price target is 13.26 USD. This implies a price increase of 489.33% is expected in the next year compared to the current price of 2.25.
For the next year, analysts expect an EPS growth of 47.03% and a revenue growth -100% for OSTX